Ann: Immutep AIPAC Ph2b Clinical Results & Update Webcast Slides, page-95

It may not be against the protocol to release data before landmark events are reached but data needs to be "analizable". It is all about statistics and ensuring the results are seen in that light. Trials pivot on the fundamental basis that results liklr apply to a population to distance away from anecdotal evidence is more the craft of backyard homepath and "such and such person swearing by the product" (which may well be true ..of that person - as opposed to population). For data to be analyzable trends need to be identifies, correlation needs to be established, multivariate/covariates analysis needs to be done partly also to "clean" the data. There may be a circumstance where in say only one person a very unexpected good or bad outcome was observed. The data for that person, in this case, pathology, needs to be studies very carefully for the good (as it may lead to key findings), ... all in all, one cannot just release the data as it comes.

Also that most trials are usually randomized as well as blinded. Releasing data as it comes potentially compromises both.